WuXi PharmaTech Disappointed With Charles River Breakup; Faces Toxicology Field Alone
This article was originally published in The Pink Sheet Daily
Executive Summary
WuXi expects to have a full service toxicology operation in China in the next five years, which would have been accelerated by a merger with Charles River. By 2015, China is expected to gain more of the global toxicology service market projected to reach $150 million to $200 million.